CNS Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.0M
- Price
- $5.83
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.67%
- Volume
- 8.1K
About
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Quick stats
Shares outstanding1.5M
Computed float1.4M
Float / shares98.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001729427
Websitehttps://www.cnspharma.com
AI Summary
AI-generated1/16
standardbullishproduct launch
Corero Network Security Launches AI-Augmented Cloud-Assist for SmartWall ONE™
Corero Network Security launched AI-Augmented Cloud-Assist for its SmartWall ONE solution, integrating cloud-delivered AI analysis with on-premises mitigation to combat evolving DDoS threats.
The new feature creates a continuous intelligence loop between cloud and on-prem environments, automating policy recommendations to reduce response times and improve accuracy.
Targeting AI data centers and service providers, the capability combines machine learning with human oversight to secure critical digital infrastructure.